Search results for "endometrial cancer"

showing 10 items of 94 documents

Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer.

2019

Background:Many experimental studies have demonstrated the importance of COX-2 in the tumor angiogenesis. Inducible iNOS is responsible for a high and stable level of nitric oxide and is expressed in response to pro-inflammatory factors.Objective:The aim of this study was to evaluate the expression of COX-2 and iNOS at the protein level and to assess their potential prognostic significance in patients with endometrial cancer.Methods:The study group consisted of 45 women with endometrial cancer divided according to the degree of histological differentiation i.e. G1, 17; G2, 15; G3, 13. The control group consisted of 15 women without neoplastic changes. The expression of studied proteins was …

0301 basic medicineTumor angiogenesisAngiogenesisPharmaceutical ScienceNitric Oxide Synthase Type IINitric oxideAndrologyangiogenesis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndometrial cancerMedicineHumansIn patientAgedmolecular markerbiologybusiness.industryEndometrial cancerProtein levelCOX-2Middle Agedneoplastic changesmedicine.diseasePrognosisReaction productEndometrial NeoplasmsiNOS030104 developmental biologychemistryPolyclonal antibodiesCyclooxygenase 2030220 oncology & carcinogenesisbiology.proteinFemaleNeoplasm GradingbusinessBiotechnologyCurrent pharmaceutical biotechnology
researchProduct

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Sy…

2021

Abstract Purpose To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer incidence and death in heterozygotes of pathogenic MMR ( path_MMR ) variants. Methods The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery (RRS) at different ages. Results Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of path_MLH1 , path_MSH2 , path_MSH6 , and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and…

0301 basic medicinemedicine.medical_treatmentDNA Mismatch RepairGynecologic surgery0302 clinical medicineMalalties hereditàriesProspective StudiesProspective cohort studyGenetics (clinical)Mismatch Repair Endonuclease PMS2Incidence (epidemiology)Middle Aged16. Peace & justiceLynch syndrome3. Good health030220 oncology & carcinogenesisFemalesyöpätauditMutL Protein Homolog 1Genetic diseasesHeterozygotemedicine.medical_specialtySalpingo-oophorectomyCirurgia ginecològicaHysterectomyArticle03 medical and health sciencesCàncer colorectalCAPP2medicineHumansLynchin oireyhtymäGynecologyperinnölliset tauditHysterectomyHEREDITARY COLORECTAL-CANCERbusiness.industryEndometrial cancerCancermedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisColorectal cancerASPIRIN030104 developmental biologyClinical researchLynch syndrome3121 General medicine internal medicine and other clinical medicinekohdunpoisto3111 BiomedicineOvarian cancerbusiness
researchProduct

Risk of second primary cancers in women diagnosed with endometrial cancer in G erman and S wedish cancer registries

2017

Along with the increasing incidence and favorable prognosis, more women diagnosed with endometrial cancer may develop second primary cancers (SPCs). We aimed at investigating risk of SPCs after endometrial cancer in Germany and Sweden to provide insight into prevention strategies for SPCs. Endometrial cancer patients diagnosed at age ≥15 years in Germany during 1997-2011 and in Sweden nationwide during 1997-2012 were selected. Standardized incidence ratios (SIRs), calculated as the ratio of observed to expected numbers of cases, were used to assess the risk of a specific second cancer after endometrial cancer for both German and Swedish datasets. Among 46,929 endometrial cancer survivors in…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAdolescentYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicineEpidemiology of cancermedicineHumansRegistriesYoung adultAgedAged 80 and overSwedenGynecologyCancer preventionbusiness.industryIncidenceEndometrial cancerIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseEndometrial NeoplasmsCancer registry030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessKidney cancerInternational Journal of Cancer
researchProduct

The role of nesfatin and selected molecular factors in various types of endometrial cancer

2019

Objectives: Endometrial cancers (ECs) are the most common gynaecological cancers in well developed countries. Diabetes and metabolic syndrome are among the biggest risk factors. Nesfatin-1, the adipokine derivative of NUCB2 (nucleobindin derivative 2) is linked to the clinical course of EC. Molecular factors, including mutations in MLH1 and MHS2 genes, c-MET and ARID1A are also related to prognosis in endometrial cancer. Material and methods: Using sections of paraffin-embedded preparations and immunohistochemistry, the expression of NESF1, MLH1, MSH2,c-MET and ARID1A were examined. Results: In this study on protein expression, EC tissues manifested (although insignificantly) an elevated ex…

AdultC-MetARID1AAdipokineMLH1chemistry.chemical_compoundNESF-1Biomarkers TumormedicineHumansNucleobindinsc-METAgedRetrospective StudiesAged 80 and overbusiness.industryEndometrial cancerMLH1Obstetrics and GynecologyMiddle AgedPrognosismedicine.diseaseARID1AImmunohistochemistryMSH2Endometrial NeoplasmsDNA-Binding ProteinschemistryMSH2endometrial cancerCancer researchImmunohistochemistryFemaleMetabolic syndromebusinessTranscription FactorsGinekologia Polska
researchProduct

Soluble and nuclear oestrogen receptor status of advanced endometrial cancer in relation to subsequent clinical prognosis

1987

Both soluble and nuclear oestrogen receptors have been measured in at least two separate sections from 72 endometrial cancers and 12 normal endometria. Concentration of oestrogen receptor is shown to be, in our hands, more meaningful when expressed per unit DNA than per unit protein, whether for soluble or nuclear receptor. Endometrial cancer cells from the central part of the tumour are shown to be receptor negative more frequently than those from peripheral tumour. Thus, in large cancers, biopsies from different areas are required before a tumour can be correctly designated as receptor positive, heterogeneous or receptor negative. The intratumoral variation of receptor status may relate t…

AdultCancer ResearchReceptor Statusmedicine.medical_specialtymedicine.drug_classestradiol h 3estrogen receptorBiologyEndometriumEndometriumCytosolInternal medicineestradiolmedicineHumansradioisotopeReceptorAgedCell NucleusEndometrial cancerMiddle Agedmedicine.diseasePrognosisunclassified drugMenopauseCell nucleusmedicine.anatomical_structureEndocrinologyOncologyNuclear receptorReceptors EstrogenSolubilityEstrogenUterine NeoplasmsCancer researchFemalediethylstilbestrolMenopauseResearch Article
researchProduct

Laparoscopic sentinel node mapping with intracervical indocyanine green injection for endometrial cancer: the SENTIFAIL study – a multicentric analys…

2020

ObjectivesLaparoscopy is commonly used for endometrial cancer treatment, and sentinel lymph node (SLN) mapping has become the standard procedure for nodal assessment. Despite the standardization of the technique, there is no definitive data regarding its failure rate. The objective of this study is to identify factors associated with unsuccessful SLN mapping in endometrial cancer patients undergoing laparoscopic SLN mapping after intracervical indocyanine green (ICG) injection.MethodsWe retrospectively evaluated a consecutive series of endometrial cancer patients who underwent laparoscopic SLN mapping with intracervical ICG injection, in four oncological referral centers from January 2016 t…

AdultIndocyanine Greenmedicine.medical_specialtyendometrial neoplasmsDatabases Factualmedicine.medical_treatmentSentinel lymph nodeuterine cancerchemistry.chemical_compoundsentinel lymph nodeUterine cancermedicineHumansColoring AgentsLaparoscopyLymph nodeAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testSentinel Lymph Node Biopsybusiness.industryEndometrial cancerObstetrics and GynecologyMiddle AgedSentinel nodemedicine.diseaseuterine neoplasmSettore MED/40 - GINECOLOGIA E OSTETRICIAmedicine.anatomical_structureOncologychemistryLymphatic MetastasisSLN and lympadenectomyFemaleLaparoscopyendometrial neoplasmLymphadenectomyRadiologyuterine neoplasmsbusinessIndocyanine greenInternational Journal of Gynecologic Cancer
researchProduct

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgeme…

2007

Abstract Objective. A multicenter non-randomized phase II study was initiated to evaluate tolerability and efficacy of pegylated liposomal doxorubicin (PLD) in combination with carboplatin in gynecologic malignancies. Methods. One hundred forty women with recurrent or advanced endometrial ( n =31), cervical or vaginal cancer ( n =31), uterine sarcomas ( n =11), or recurrent platinum-sensitive ovarian cancer ( n =67) received six courses of PLD 40 mg/m 2 and carboplatin (AUC 6) every 28 days. Results. Hematological toxicities with NCI-CTC grade 3/4 were anemia in 8%, thrombocytopenia in 14%, neutropenia in 24%, and febrile neutropenia in 2% of 652 cycles. Grade 3/4 non-hematological toxiciti…

AdultOncologymedicine.medical_specialtyGenital Neoplasms FemalePhases of clinical researchNeutropeniaGastroenterologyDrug Administration ScheduleCarboplatinPolyethylene Glycolschemistry.chemical_compoundInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedAged 80 and overVaginal cancerUterine sarcomabusiness.industryEndometrial cancerObstetrics and GynecologyMiddle Agedmedicine.diseaseCarboplatinOncologychemistryDoxorubicinFemaleOvarian cancerbusinessFebrile neutropeniaGynecologic Oncology
researchProduct

p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer

2011

Abstract Objective P53 tumor suppressor gene plays a role in endometrial carcinogenesis. Former studies described correlations between p53 protein overexpression in endometrial cancer and prognostic factors, measured by immunohistochemistry. But data is still controversial. The aim of this study was to measure p53 and phospho-p53 overexpression by Western blot and evaluate correlations between overexpression and prognostic and clinical factors. Phospho-p53 seems to be the functional p53 protein and was examined for the first time in endometrial cancer. Methods 40 patients with endometrial cancer were included in the study. A control group of 20 patients with normal endometrial tissue sample…

AdultOncologymedicine.medical_specialtyNegative progesterone receptorBlotting WesternKaplan-Meier EstimateDiseaseAdenocarcinomaDisease-Free SurvivalBody Mass IndexDiabetes ComplicationsWestern blotRecurrenceInternal medicineBiomarkers TumormedicineHumansIn patientPathologicalAgedAged 80 and overmedicine.diagnostic_testbusiness.industryEndometrial cancerObstetrics and GynecologyMiddle AgedGenes p53Prognosismedicine.diseaseEndometrial NeoplasmsUp-RegulationExact testOncologyCase-Control StudiesImmunohistochemistryElectrophoresis Polyacrylamide GelFemaleTumor Suppressor Protein p53Receptors ProgesteronebusinessGynecologic Oncology
researchProduct

Genetic Imbalances in Precursor Lesions of Endometrial Cancer Detected by Comparative Genomic Hybridization

2000

Endometrial hyperplasia is regarded as a precursor lesion of endometrioid adenocarcinomas of the endometrium. The genetic events involved in the multistep process from normal endometrial glandular tissue to invasive endometrial carcinomas are primarily unknown. We chose endometrial hyperplasia as a model for identifying chromosomal aberrations occurring during carcinogenesis. Comparative genomic hybridization (CGH) was performed on 47 formalin-fixed, paraffin-embedded specimens of endometrial hyperplasia using the microdissection technique to increase the number of tumor cells in the samples and reduce contamination from normal cells. CGH analysis revealed that 24 out of 47 (51%) samples ha…

AdultPathologymedicine.medical_specialtyGenotypeShort CommunicationsBiologyAdenocarcinomaPathology and Forensic MedicinemedicineAtypiaHumansMicrodissectionAgedNeoplasm StagingAged 80 and overEndometrial cancerNucleic Acid HybridizationHyperplasiaMiddle Agedmedicine.diseaseEndometrial hyperplasiaEndometrial NeoplasmsPhenotypeDysplasiaAdenocarcinomaFemalePrecancerous ConditionsComparative genomic hybridization
researchProduct

The Patient and Observer Scar Assessment Scale to Evaluate the Cosmetic Outcomes of the Robotic Single-Site Hysterectomy in Endometrial Cancer

2017

ObjectiveThe objective of this study was to evaluate the cosmetic outcome of robotic single-site hysterectomy (RSSH) in early-stage endometrial cancer.MethodsWe prospectively collected patient demographics, operative times, complications, pathologic results, and length of stay on all patients who underwent RSSH for early-stage endometrial cancer. The Patient and Observer Scar Assessment Scale (POSAS) was used for the evaluation of the cosmetic outcome.ResultsForty-five patients were included in our study from January 2012 to October 2015. The median age of patients was 63 years (range, 35–84 years), and the median body mass index was 26.5 kg/m2 (range, 18–39 kg/m2). No laparoscopic/laparoto…

AdultRobotic Surgical Proceduremedicine.medical_specialtymedicine.medical_treatmentPOSASScarsHysterectomyCicatrix03 medical and health sciences0302 clinical medicineEndometrial cancerRobotic Surgical ProceduresObstetrics and gynaecologymedicineHumansEndometrial NeoplasmMass indexProspective StudiesProspective cohort studyAgedAged 80 and over030219 obstetrics & reproductive medicineHysterectomybusiness.industryEndometrial cancerObstetrics and GynecologyPostoperative complicationMiddle Agedmedicine.diseaseEndometrial NeoplasmsSurgeryRobotic single-site hysterectomyProspective StudieOncology030220 oncology & carcinogenesisFemaleMedian bodymedicine.symptombusinessHumanInternational Journal of Gynecologic Cancer
researchProduct